Relmada Therapeutics Inc (RLMD)
3.00
-0.04
(-1.32%)
USD |
NASDAQ |
May 31, 16:00
3.01
+0.01
(+0.33%)
Pre-Market: 20:00
Relmada Therapeutics Research and Development Expense (Annual): 54.81M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 54.81M |
| December 31, 2022 | 113.32M |
| December 31, 2021 | 90.62M |
| December 31, 2020 | 35.97M |
| December 31, 2019 | 3.514M |
| June 30, 2019 | 7.025M |
| Date | Value |
|---|---|
| June 30, 2018 | 2.943M |
| June 30, 2017 | 1.294M |
| June 30, 2016 | 6.207M |
| June 30, 2015 | 7.872M |
| June 30, 2014 | 0.84M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
3.514M
Minimum
2019
113.32M
Maximum
2022
50.88M
Average
45.39M
Median
Research and Development Expense (Annual) Benchmarks
| Cyclacel Pharmaceuticals Inc | 19.16M |
| Lifecore Biomedical Inc | 8.736M |
| Harrow Inc | 6.652M |
| Corvus Pharmaceuticals Inc | 16.53M |
| Aquestive Therapeutics Inc | 13.10M |